Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Outlook Therapeutics, Inc. - Common Stock (NQ:OTLK)

1.685 -0.065 (-3.71%)
Streaming Delayed Price Updated: 1:23 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Outlook Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
Via Benzinga
Exposures Product Safety
Top 3 Health Care Stocks That Could Blast Off This Month
Via Benzinga
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Nasdaq Down Over 100 Points; HP Shares Plunge
Via Benzinga
Dow Falls Over 100 Points; US Crude Oil Stocks Decline
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
US Stocks Mixed; Economy Grows By 2.8% In Q3
Via Benzinga
Topics Economy
Exposures Economy
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Outlook Therapeutics reports ONS-5010 missed noninferiority endpoint in NORSE EIGHT trial for wet AMD but showed vision improvement and safety profile. 
Via Benzinga
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
OTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024
OTLK stock results show that Outlook Therapeutics beat analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
Via MarketBeat
3 Undervalued Gems Set to Soar 1,000% by 2026
Discover the fundamentals behind three undervalued stocks to buy in the oil and gas, advertising, and biotechnology industries. 
Via InvestorPlace
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
Outlook Therapeutics (NASDAQ: OTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target. 
Via MarketBeat
OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024
OTLK stock results show that Outlook Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
Insiders Buying Outlook Therapeutics And 2 Other Stocks
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. 
Via Benzinga
Gold Moves Lower; Lululemon Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Dips 200 Points; Nike Shares Fall After Q3 Results
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0.54% to 39,565.50 while the NASDAQ rose 0.04% to 16,408.74. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?
Outlook Therapeutics stock sees uptick as European Medicines Agency committee issues positive opinion on ONS-5010/LYTENAVA for wet age-related macular degeneration (wet AMD). Strong trading volume... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed higher by around 47 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
7 of the Best Speculative Stocks You Can Snag for Less Than $1
Although speculative stocks under $1 are by their very nature extremely risky, these ideas might have enough to go the distance. 
Via InvestorPlace
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.